Literature DB >> 15140629

Opioid receptor desensitization contributes to thermal hyperalgesia in infant rats.

Jing-Gen Liu1, Cynthia R Rovnaghi, Sarita Garg, K J S Anand.   

Abstract

Central nociceptive processing includes spinal and supraspinal neurons, but the supraspinal mechanisms mediating changes in pain threshold remain unclear. We investigated the role of forebrain neurons in capsaicin-induced hyperalgesia. Long-Evans rat pups at 21 days were randomized to undisturbed control group, or to receive tactile stimulation, saline injection (0.9% w/v) or capsaicin injection (0.01% w/v) applied to each paw at hourly intervals. Thermal paw withdrawal latency was measured 1 h later, forebrains were removed and purified forebrain neuronal membranes were assayed for adenylyl cyclase activity and opioid receptor function. Capsaicin-injected rats had decreased thermal latency (P < 0.0001) compared to the other groups. Neuronal membranes showed increased basal (P = 0.0003) and forskolin-stimulated (P=0.0002) adenylyl cyclase activity in the capsaicin group compared to other groups. The selective mu-opioid receptor agonist, [D-Ala2, N-Me-Phe4, Gly5-ol]enkephalin (DAMGO) was less effective in inhibiting adenylyl cyclase activity in the capsaicin group (P < 0.001) compared to other groups. These effects were naloxone-reversible and pertussis toxin-sensitive (P < 0.01) in the control, tactile stimulation and saline injection groups but not in the capsaicin group. Binding capacity and affinity for micro-opioid receptors were similar in all four groups, suggesting that receptor downregulation was not involved. Exposure to DAMGO increased [35S]GTPgammaS binding to neuronal membranes from the control, tactile and saline groups (P<0.001) in a naloxone-reversible and pertussis toxin-sensitive manner (P < 0.01) but not in the capsaicin group, suggesting mu-opioid receptor desensitization. Dose responses to systemic morphine were also reduced in the capsaicin group compared to the tactile group (P < 0.05). Capsaicin-induced hyperalgesia in 21-day-old rats was associated with an uncoupling of micro-opioid receptors in the forebrain. Opioid receptor desensitization in the forebrain may reduce opioidergic inputs to the descending inhibitory controls, associated with behavioral hyperalgesia and reduced responsiveness to morphine analgesia in capsaicin-injected young rats. Copyright 2004 Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15140629     DOI: 10.1016/j.ejphar.2004.03.042

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

Review 1.  Pharmacological therapy for analgesia and sedation in the newborn.

Authors:  K J S Anand; R W Hall
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-11       Impact factor: 5.747

2.  Social and environmental influences on opioid sensitivity in rats: importance of an opioid's relative efficacy at the mu-receptor.

Authors:  Mark A Smith; Kara A Chisholm; Paul A Bryant; Jennifer L Greene; Jacob M McClean; William W Stoops; David L Yancey
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

Review 3.  Regulation of opioid receptor signalling: implications for the development of analgesic tolerance.

Authors:  Karim Nagi; Graciela Piñeyro
Journal:  Mol Brain       Date:  2011-06-13       Impact factor: 4.041

4.  Long-Term Outcomes after Protocolized Sedation versus Usual Care in Ventilated Pediatric Patients.

Authors:  R Scott Watson; Lisa A Asaro; James H Hertzog; Lauren R Sorce; Alicia G Kachmar; Leslie A Dervan; Derek C Angus; David Wypij; Martha A Q Curley
Journal:  Am J Respir Crit Care Med       Date:  2018-06-01       Impact factor: 30.528

5.  Adult spinal opioid receptor μ1 expression after incision is altered by early life repetitive tactile and noxious procedures in rats.

Authors:  Nynke J van den Hoogen; Roel Ri van Reij; Jacob Patijn; Dick Tibboel; Elbert A J Joosten
Journal:  Dev Neurobiol       Date:  2018-02-28       Impact factor: 3.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.